Diminished in vitro antibacterial activity of oxacillin against clinical isolates of borderline oxacillin-resistant Staphylococcus aureus

Clinical Microbiology and Infection

Volumn 16, Issue 7, 2010, Pages 979-985

  Croes, S ^a,b   Beisser, P S ^a   Terporten, P H ^a   Neef, C ^b   Deurenberg, R H ^a   Stobberingh, E E ^a  

^a Department of Medical Microbiology ^*  (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BORSA; Daptomycin; Linezolid; Oxacillin; Time kill experiments; Vancomycin

Indexed keywords

BETA LACTAMASE; DAPTOMYCIN; LINEZOLID; OXACILLIN; PENICILLIN BINDING PROTEIN 2A; PLASMID DNA; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; DRUG RESPONSE; ENZYME SYNTHESIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PLASMID; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

EID: 77954636348     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.02956.x     Document Type: Article

References (31)

1. Nelson L, Cockram CS, Lui G. Community case of methicillin-resistant Staphylococcus aureus infection. Emerg Infect Dis 2006, 12:172-174.
2. Nadarajah J, Lee MJ, Louie L. Identification of different clonal complexes and diverse amino acid substitutions in penicillin-binding protein 2 (pbp2) associated with borderline oxacillin resistance in Canadian Staphylococcus aureus isolates. J Med Microbiol 2006, 55:1675-1683.
3. Massidda O, Montanari MP, Varaldo PE. Evidence for a methicillin-hydrolysing beta-lactamase in Staphylococcus aureus strains with borderline susceptibility to this drug. FEMS Microbiol Lett 1992, 71:223-227.
4. Keseru JS, Gal Z, Barabas G, Benko I, Szabo I. Investigation of beta-lactamases in clinical isolates of Staphylococcus aureus for further explanation of borderline methicillin resistance. Chemotherapy 2005, 51:300-304.
5. Varaldo PE. The 'borderline methicillin-susceptible'Staphylococcus aureus. J Antimicrob Chemother 1993, 31:1-4.
6. Hackbarth CJ, Kocagoz T, Kocagoz S, Chambers HF. Point mutations in Staphylococcus aureus pbp 2 gene affect penicillin-binding kinetics and are associated with resistance. Antimicrob Agents Chemother 1995, 39:103-106.
7. Tomasz A, Drugeon HB, de Lencastre HM, Jabes D, McDougall L, Bille J. New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the pbp 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity. Antimicrob Agents Chemother 1989, 33:1869-1874.
8. Balslev U, Bremmelgaard A, Svejgaard E, Havstreym J, Westh H. An outbreak of borderline oxacillin-resistant Staphylococcus aureus (BORSA) in a dermatological unit. Microb Drug Resist 2005, 11:78-81.
9. Thomsen MK, Rasmussen M, Fuursted K. Clonal spread of Staphylococcus aureus with reduced susceptibility to oxacillin in a dermatological hospital unit. Acta Derm Venereol 2006, 86:230-234.
10. Hirano L, Bayer AS. Beta-lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci. Antimicrob Agents Chemother 1991, 35:685-690.
11. Pefanis A, Thauvin-Eliopoulos C, Eliopoulos GM, Moellering RC. Activity of ampicillin-sulbactam and oxacillin in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus. Antimicrob Agents Chemother 1993, 37:507-511.
12. Barg N, Chambers H, Kernodle D. Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the hyperproduction of beta-lactamase. Antimicrob Agents Chemother 1991, 35:1975-1979.
13. Donker GA, Deurenberg RH, Driessen C, Sebastian S, Nys S, Stobberingh EE. The population structure of Staphylococcus aureus among general practice patients from the Netherlands. Clin Microbiol Infect 2009, 15:137-143.
14. Pitkala A, Salmikivi L, Bredbacka P, Myllyniemi AL, Koskinen MT. Comparison of tests for detection of beta-lactamase-producing staphylococci. J Clin Microbiol 2007, 45:2031-2033.
15. Massidda O, Montanari MP, Mingoia M, Varaldo PE. Borderline methicillin-susceptible Staphylococcus aureus strains have more in common than reduced susceptibility to penicillinase-resistant penicillins. Antimicrob Agents Chemother 1996, 40:2769-2774.
16. Performance standards for antimicrobial susceptibility testing-seventh edition: approved standard m7-a7 2007, Wayne, PA, USA, Clinical and Laboratory Standards Institute
17. Sherris JC. Problems in in vitro determination of antibiotic tolerance in clinical isolates. Antimicrob Agents Chemother 1986, 30:633-637.
18. Isenberg HD. Tests to assess bacterial activity-time-kill assay. Clinical microbiology procedures handbook 1992, 14-20. Hindler J. In, ed, Washington, D.C, American Society for Microbiology
19. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992, 36:2709-2714.
20. Ausubel FM, Brent R, Kingston RE. Current protocols in molecular biology 2008, New York, NY, John Wiley & Sons, Inc.
21. Yoshida R, Kuwahara-Arai K, Baba T, Cui L, Richardson JF, Hiramatsu K. Physiological and molecular analysis of a meca-negative Staphylococcus aureus clinical strain that expresses heterogeneous methicillin resistance. J Antimicrob Chemother 2003, 51:247-255.
22. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (pk/pd) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005, 55:601-607.
23. Armitage P, Berry G. Statistical methods in medical research 1987, 2nd edn, Oxford, Blackwell Scientific Publications
24. Wilson K, Goulding KH. Principles and techniques of practical biochemistry 1986, 3rd edn, London, Edward Arnold
25. Gunnison JB, Fraher MA, Jawetz E. Persistence of Staphylococcus aureus in penicillin in vitro. J Gen Microbiol 1964, 35:335-349.
26. Massidda O, Mingoia M, Fadda D, Whalen MB, Montanari MP, Varaldo PE. Analysis of the beta-lactamase plasmid of borderline methicillin-susceptible Staphylococcus aureus: focus on bla complex genes and cadmium resistance determinants cadd and cadx. Plasmid 2006, 55:114-127.
27. Baba T, Takeuchi F, Kuroda M. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002, 359:1819-1827.
28. Czock D, Keller F. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn 2007, 34:727-751.
29. Tsuji BT, Yang JC, Forrest A, Kelchlin PA, Smith PF. In vitro pharmacodynamics of novel rifamycin abi-0043 against Staphylococcus aureus. J Antimicrob Chemother 2008, 62:156-160.
30. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10. quiz 11-12
31. Skinner S, Murray M, Walus T, Karlowsky JA. Failure of cloxacillin in treatment of a patient with borderline oxacillin-resistant Staphylococcus aureus endocarditis. J Clin Microbiol 2009, 47:859-861.